Cannabidiol is a medicine that is being developed for the treatment of TSC patients who experience inadequately-controlled seizures. It is being developed as an oral medicine to be added to existing treatment options for TSC (‘add-on therapy’). Cannabidiol has a unique chemical structure that makes it prevent or stop seizures and is thought to have cumulative effect. If licensed, cannabidiol will offer an add-on treatment option for patients with TSC who experience inadequately-controlled seizures.
Dabigatran etexilate is an oral drug that acts by preventing clots from forming and blocking blood vessels. It is already available for the treatment and prevention of stroke and other types of blood clots affecting blood vessels and organs in the body. By preventing clots from forming, it can prevent future embolic strokes.